XML 23 R13.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Segment Data | 9 Months Ended
--- | ---
Jun. 30, 2024
Segment Reporting [Abstract] |
Segment Data | Segment Data The Company's organizational structure is based upon three worldwide business segments: BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional (“Interventional”). The Company's segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services. Segment disclosures are on a performance basis consistent with internal management reporting. The Company evaluates performance of its business segments and allocates resources to them primarily based upon segment operating income, which represents revenues reduced by product costs and operating expenses. Revenues by segment, organizational unit and geographical areas for the three and nine-month periods are detailed below. The Company has no material intersegment revenues.
| Three Months Ended June 30,
(Millions of dollars) | 2024 |  | 2023
| United States |  | International |  | Total |  | United States |  | International |  | Total
Medical |  |  |  |  |  |  |  |  |  |  |
Medication Delivery Solutions | $ | 670 |  |  | $ | 453 |  |  | $ | 1,123 |  |  | $ | 628 |  |  | $ | 459 |  |  | $ | 1,086 |
Medication Management Solutions | 680 |  |  | 160 |  |  | 840 |  |  | 587 |  |  | 167 |  |  | 754 |
Pharmaceutical Systems | 158 |  |  | 437 |  |  | 594 |  |  | 186 |  |  | 408 |  |  | 594 |
Total segment revenues | $ | 1,508 |  |  | $ | 1,050 |  |  | $ | 2,558 |  |  | $ | 1,400 |  |  | $ | 1,033 |  |  | $ | 2,434 |
Life Sciences |  |  |  |  |  |  |  |  |  |  |
Integrated Diagnostic Solutions | $ | 405 |  |  | $ | 491 |  |  | $ | 896 |  |  | $ | 398 |  |  | $ | 460 |  |  | $ | 858 |
Biosciences | 141 |  |  | 222 |  |  | 363 |  |  | 148 |  |  | 220 |  |  | 368 |
Total segment revenues | $ | 546 |  |  | $ | 714 |  |  | $ | 1,260 |  |  | $ | 546 |  |  | $ | 680 |  |  | $ | 1,226 |
Interventional |  |  |  |  |  |  |  |  |  |  |
Surgery | $ | 283 |  |  | $ | 93 |  |  | $ | 376 |  |  | $ | 298 |  |  | $ | 90 |  |  | $ | 388 |
Peripheral Intervention | 263 |  |  | 225 |  |  | 488 |  |  | 256 |  |  | 225 |  |  | 481 |
Urology and Critical Care | 297 |  |  | 78 |  |  | 375 |  |  | 272 |  |  | 77 |  |  | 349 |
Total segment revenues | $ | 844 |  |  | $ | 396 |  |  | $ | 1,240 |  |  | $ | 826 |  |  | $ | 392 |  |  | $ | 1,218 |
Other (a) | $ | (6) |  |  | $ | (62) |  |  | $ | (67) |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Total Company revenues | $ | 2,891 |  |  | $ | 2,098 |  |  | $ | 4,990 |  |  | $ | 2,772 |  |  | $ | 2,106 |  |  | $ | 4,878 |
(a) Represents the recognition of accruals resulting from recent developments relating to the Italian government medical device pay back legislation, as well as another legal matter, and which substantially relate to years prior to the current fiscal year. Such amounts were not allocated to the Company’s reportable segments and these matters are further discussed in Note 5.
| Nine Months Ended June 30,
(Millions of dollars) | 2024 |  | 2023
| United States |  | International |  | Total |  | United States |  | International |  | Total
Medical |  |  |  |  |  |  |  |  |  |  |
Medication Delivery Solutions | $ | 1,971 |  |  | $ | 1,310 |  |  | $ | 3,282 |  |  | $ | 1,863 |  |  | $ | 1,332 |  |  | $ | 3,195 |
Medication Management Solutions | 1,883 |  |  | 475 |  |  | 2,359 |  |  | 1,701 |  |  | 483 |  |  | 2,184 |
Pharmaceutical Systems | 442 |  |  | 1,154 |  |  | 1,596 |  |  | 478 |  |  | 1,092 |  |  | 1,570 |
Total segment revenues | $ | 4,297 |  |  | $ | 2,940 |  |  | $ | 7,237 |  |  | $ | 4,042 |  |  | $ | 2,907 |  |  | $ | 6,949 |
Life Sciences |  |  |  |  |  |  |  |  |  |  |
Integrated Diagnostic Solutions | $ | 1,286 |  |  | $ | 1,451 |  |  | $ | 2,737 |  |  | $ | 1,327 |  |  | $ | 1,371 |  |  | $ | 2,699 |
Biosciences | 426 |  |  | 689 |  |  | 1,115 |  |  | 444 |  |  | 660 |  |  | 1,104 |
Total segment revenues | $ | 1,712 |  |  | $ | 2,139 |  |  | $ | 3,852 |  |  | $ | 1,772 |  |  | $ | 2,031 |  |  | $ | 3,803 |
Interventional |  |  |  |  |  |  |  |  |  |  |
Surgery | $ | 851 |  |  | $ | 273 |  |  | $ | 1,124 |  |  | $ | 880 |  |  | $ | 252 |  |  | $ | 1,131 |
Peripheral Intervention | 762 |  |  | 669 |  |  | 1,431 |  |  | 748 |  |  | 635 |  |  | 1,383 |
Urology and Critical Care | 930 |  |  | 234 |  |  | 1,165 |  |  | 794 |  |  | 225 |  |  | 1,019 |
Total segment revenues | $ | 2,543 |  |  | $ | 1,177 |  |  | $ | 3,720 |  |  | $ | 2,421 |  |  | $ | 1,112 |  |  | $ | 3,533 |
Other (a) | $ | (6) |  |  | $ | (62) |  |  | $ | (67) |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Total Company revenues | $ | 8,546 |  |  | $ | 6,195 |  |  | $ | 14,741 |  |  | $ | 8,235 |  |  | $ | 6,050 |  |  | $ | 14,285 |
(a) Represents the recognition of accruals resulting from recent developments relating to the Italian government medical device pay back legislation, as well as another legal matter, and which substantially relate to years prior to the current fiscal year. Such amounts were not allocated to the Company’s reportable segments and these matters are further discussed in Note 5. Segment income for the three and nine-month periods was as follows:
| Three Months Ended June 30, |  | Nine Months Ended June 30,
(Millions of dollars) | 2024 |  | 2023 |  | 2024 |  | 2023
Income Before Income Taxes |  |  |  |  |  |  |
Medical (a) | $ | 753 |  |  | $ | 588 |  |  | $ | 1,950 |  |  | $ | 1,783 |
Life Sciences | 387 |  |  | 343 |  |  | 1,174 |  |  | 1,171 |
Interventional | 365 |  |  | 323 |  |  | 1,044 |  |  | 922 |
Total Segment Operating Income | 1,505 |  |  | 1,254 |  |  | 4,168 |  |  | 3,875 |
Integration, restructuring and transaction expense | (112) |  |  | (70) |  |  | (288) |  |  | (175) |
Net interest expense | (89) |  |  | (95) |  |  | (265) |  |  | (299) |
Other unallocated items (b) | (804) |  |  | (618) |  |  | (2,124) |  |  | (1,920) |
Total Income Before Income Taxes | $ | 500 |  |  | $ | 471 |  |  | $ | 1,491 |  |  | $ | 1,481 |
(a)The amounts for the three and nine months ended June 30, 2023 included charges recorded to Cost of products sold of $90 million to adjust estimated future product remediation costs. (b)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration